Teleflex Incorporated (TFX) Earnings Call Transcript & Summary

February 27, 2025

New York Stock Exchange US Health Care Health Care Equipment and Supplies earnings 67 min

Earnings Call Speaker Segments

Larry Keusch

executive
#1

Hello, everyone, and thanks for joining us on the Teleflex Incorporated Fourth Quarter 2024 Earnings Conference Call this morning. You can find the press release and the slides that go along with this call on our website, teleflex.com. Just a note that a replay is going to be made available on our website as well. If you'd like to listen to that replay, our press releases from this morning have the details you need. On the call with us today are Liam Kelly, who serves as Chairman, President and Chief Executive Officer; Thomas Powell, our Executive Vice President and Chief Financial Officer; and John Deren, Corporate Vice President and Chief Accounting Officer. Prepared remarks will be given by Liam, Tom and John, and after that we'll move to the Q&A portion of the call. Before we get started, I want to remind everyone that certain matters we'll discuss during this conference call will include forward-looking statements about future events, as described in the slides posted in the Investor Relations section of the Teleflex website. We want to caution you that these statements are forward-looking in nature and are subject to risks and uncertainties, and actual events or results may differ materially. Among the factors that could cause actual results or events to differ materially are those referenced in our press release, along with our filings with the SEC, including our Form 10-K, which you can access on our website; and now I'll hand the call over to Liam for his remarks.

Liam Kelly

executive
#2

Thanks, Larry, and good morning to all of you. To start, I'd like to talk about a change in Teleflex's senior leadership. Tom Powell, our Executive Vice President and Chief Final Officer, has let the Board know he plans to retire, with that taking effect on April 1, 2025. Tom has been someone we could count on, and I'd like to express my appreciation for everything he has done for Teleflex. Across the last 13 years, Tom was a key force behind our adjusted operating margins, which rose 800 basis points between 2012 and 2024. As the company expanded, Tom also assembled a superb global finance team that will be crucial to keeping us well positioned going forward. I'd also like to call attention to how much emphasis Tom placed on succession planning. Making sure the finance leadership transition goes smoothly. Last, thank you for agreeing to remain with us in a consulting role for the next 12 months. It's my pleasure to share that John Deren, Corporate Vice President and Teleflex's Chief Accounting Officer, will take over from Tom as Executive Vice President and Chief Financial Officer, effective April 2, 2025. I'm eager to work closely with John. Given his deep familiarity with Teleflex and more than 30 years of financial management and reporting experience with public companies, John will be vital as we keep executing our growth strategy. Now let's move to financial results. In the fourth quarter, Teleflex revenues came in at $795.4 million, rising 2.8% year-over-year on a GAAP basis and 3.2% higher on an adjusted constant currency basis. Our Interventional and Surgical businesses performed well in the fourth quarter, posting adjusted constant currency growth of 18.7% and 12.3%, respectively. Palette Life Sciences revenues came in above the top end of our $73 million to $75 million guidance for 2024. Despite these solid results, adjusted constant currency revenues for the fourth quarter fell $10.2 million short of the bottom end of our revenue expectations. Roughly half of that was tied to Interventional Urology. The rest of the revenue gap stemmed from fewer hospitalizations compared with a year earlier because of flu and COVID-19, which hurt our CVC business within our Vascular business unit. Adjusted earnings per share for the fourth quarter climbed 15.1% to $3.89. I'll now hand things over to Tom for his remarks.

Tom Powell

executive
#3

Thank you, Liam. My career has been lengthy and rewarding, and it included more than 20 years serving as CFO of a public company. The 13 years I spent at Teleflex were especially enjoyable, and I take great pride in what our team achieved together while I was there, having successfully grown into our position as a leading global provider of medical devices. After talking it over with my family first, we concluded that now was the right moment for me to retire. A big factor in my decision was that, across the last several years, I had worked through our internal planning process to build a strong bench of internal succession candidates. After that, we conducted a proper search. It included strong applicants from within Teleflex as well as from outside, and our Board was involved in the process. The Board concluded that John Deren was the best fit for Teleflex. I have strong faith in the Teleflex management team, and I'm eager to see Teleflex keep succeeding in the future. As we said in this morning's 8-K, once I step down, I've agreed to act as a consultant to the company until March 31, 2026, which will help with continuity and make the transition smoother. Now I'll move on to reviewing the quarter, starting with gross margin since we already talked about revenues. During the quarter, adjusted gross margin came in at 60.1%, matching the prior year period, since gains from M&A mix and price were mostly canceled out by inflation and foreign exchange. In the fourth quarter, adjusted operating margin reached 27.6%, a 130 basis point improvement year-over-year, driven by strict spending controls that helped bring operating expense down as a percentage of sales. Now for our 2024 results. Across the full year 2024, adjusted constant currency revenues rose 3.1% year-over-year, and adjusted earnings per share totaled $14.01. Both our Interventional and EMEA businesses delivered strong performances in 2024, with adjusted constant currency growth of 14.8% and 7.3%, respectively. Surgical kept performing at a high level, delivering adjusted constant currency growth of 6.1%, helped along by ongoing sales of the Titan stapler. In Interventional Urology, revenue rose 3.7% on an adjusted constant currency basis, as gains from Palette were mostly canceled out by weakness in the UroLift business. Margin improvement in 2024 was strong: adjusted gross margin grew 120 basis points, while adjusted operating margin rose 60 basis points compared with the prior year. The expansion in adjusted gross margin came from ending the MSA, acquiring Palette, and beneficial pricing. Growth in adjusted operating margin was mainly the result of adjusted gross margin flowing through. Operating cash flow was robust, climbing 24.7% year-over-year to reach $638.3 million in 2024, up from $511.7 million the year before. Increased cash flow from operations compared to last year was helped by better operating results, plus gains in working capital that came from bringing inventory levels down and a $37 million boost tied to ending our U.S. pension plan. At the close of the quarter, net leverage stood at roughly 1.5x. Lastly, when the yearly goodwill impairment test for Q4 2024 was completed, it showed that the Interventional Urology North America reporting unit—part of our Americas operating segment—had a carrying value exceeding its fair value. This stemmed from a prolonged period of soft top-line performance driven by persistent end-market challenges, along with changes in competitive dynamics expected in the near to medium term. As a result, in Q4 of 2024 we booked a $240 million noncash goodwill impairment charge. With that, I'll now turn it over to John Deren.

John Deren

executive
#4

Thank you, Tom. I'm grateful for the trust that Liam, Tom, and the Board have placed in me as I step into the Chief Financial Officer position at Teleflex. It's a tremendous privilege to take on this responsibility, and I'm thrilled about the chance ahead. The leadership Tom has shown throughout the years has built a strong foundation, and I'm dedicated to expanding upon it as we enter this new phase; given how capable our management team is, I have no doubt we can keep propelling Teleflex forward. Before I move into guidance, I want to address the accelerated share repurchase that we made public this morning. The $300 million accelerated share repurchase takes effect tomorrow, February 28; our expectation is that this accelerated share repurchase will wrap up during the second quarter of 2025. Through this stock repurchase, we finished off the existing $500 million share repurchase program that our Board of Directors authorized back in July of 2024. As part of how we approach capital allocation on an ongoing basis, we'll stay opportunistic when it comes to repurchasing shares going forward. Now I'd like to shift to our 2025 financial guidance; for 2025, we anticipate adjusted constant currency growth between 1% and 2%. Remember that this projection doesn't include the $13.8 million hit from that Italian action back in Q2 of 2024. For 2025, we're figuring on about $55 million — which works out to a 180 basis point drag on revenue — coming from FX translation, assuming a euro-to-dollar rate of 103. Looking ahead to 2025, our guidance bakes in continued strain on our Interventional Urology segment tied to weakness in UroLift. For our OEM segment, we're starting to observe a growing pattern of what we believe will be a short-term pushback in orders from customers. That's being caused by their emphasis on managing stock levels, plus the contract that we lost and talked about during the third quarter of 2024 earnings. Together, those factors will produce a decline in growth for the full year. Beyond that, we also expect volume-based procurement to affect our surgical business in China over the course of the year. For 2025, we're projecting adjusted earnings per share between $13.95 and $14.35. For fiscal year guidance on revenue and adjusted EPS, we've landed on the lower bound of each range—figures we consider both realistic and attainable—and we're quite confident the team can hit those marks in 2025. A few assumptions sit behind that 2025 outlook, which you'll want for your models: adjusted gross margin landing somewhere in the 60.25% to 61% band, adjusted operating margin running 26.6% to 27%, net interest expense of roughly $75 million (this reflects the accelerated share repurchase's effect), and an adjusted tax rate around 13.5%. One more thing—once the Vascular Intervention acquisition closes, we'll come back and revise that 2025 interest expense figure. Also, there were roughly 45.5 million weighted average shares, which takes into account a $300 million accelerated share repurchase. Tariffs already in force are factored into what we're projecting for 2025, but ones that have just been proposed are not. When it comes to tariffs on U.S. imports, our biggest vulnerability involves production we run in Mexico. Should duties be imposed on medical device products originating there, we'd see a negative impact on our financial results, and the 2025 guidance we shared today might be affected as well. Turning to the full-year revenue outlook, it incorporates a constant-currency decrease of 3% to 4% for the first quarter, and that figure excludes an expected $14 million impact from movements in foreign exchange rates compared with the prior year. This decline for the first quarter of 2025, measured against the same period a year earlier, reflects the persistent challenges arising from the headwinds we've already discussed. With that, I'll return the floor to Liam, who will walk through the revisions to our strategic framework and our focus on delivering shareholder value.

Liam Kelly

executive
#5

Thanks, John. Let's turn now to the question of how we create value. Four pillars form the foundation of our company strategy. These include a focus on generating durable top-line growth while also expanding earnings and margins. We're happy to report today that Teleflex has entered a definitive agreement to acquire essentially the entirety of the Vascular Intervention business owned by Biotronik SE & Co. KG, a privately held firm, for an estimated cash payment at closing of about EUR 760 million, subject to certain adjustments set out in the purchase agreement, among them certain working capital, not transferring and other customary adjustments. For a long time, our Teleflex Interventional business has been a foundation for both growth and innovation across our diversified lineup. With an opportunity to generate revenue growth that can be sustained while also lifting margins, buying Vascular Intervention plays a central role in our value creation plan, allowing us to keep building on that solid base. By bringing Biotronik's products into the fold, we think Teleflex will pick up significant scale, grow its footprint in the cath lab, and be set up for ongoing healthy expansion. The portfolio we expect to pick up covers a wide range of vascular intervention devices, including drug-coated balloons, drug-eluting stents, covered stents, balloon and self-expanding bare metal stents, plus balloon catheters. Let me walk through why buying the Vascular Intervention business makes strategic sense. Back in 2017 we picked up Vascular Solutions, and this deal does something similar — it gives Teleflex a bigger footprint in the cath lab once again. What we're getting here is a wide-ranging set of interventional therapeutic devices, and those will pair well with the complex percutaneous coronary intervention access products Teleflex already has firmly in place. On top of that, we'll be strengthening and growing the interventional sales team we've had for years. With coronary and peripheral interventional operations combined, this purchase meaningfully broadens Teleflex's reach in the market. We'll keep putting money into our own R&D as a top priority, and because the merged businesses are larger, there's room to expand even further. Worldwide demand for peripheral intervention is climbing quickly, with expansion across the globe projected at a high single-digit rate. In our view, bringing the Vascular Intervention business into the fold would allow Teleflex to plant a flag in the neighboring peripheral space, while also strengthening the position we're already building in coronary interventions. Within our current complex PCI lineup, there are products designed for use in challenging coronary procedures. And once we bring aboard the portfolio of innovative products we intend to acquire, we'll be positioned to elevate our technology offerings across both coronary and peripheral interventions. Being able to take part in combined coronary approaches — using drug-coated balloons, drug-eluting stents, and the emerging potential of resorbable scaffold technologies — would broaden the procedure base we can currently address. Several items we already sell carry peripheral uses. Buying this company gives us a way to get those items into customers' hands. On top of that, as our lineup grows, our reps can put their clinical expertise to work and have more conversations with clinicians. We see chances to broaden the U.S. footprint of the products we expect to pick up in the deal. Through our commercial initiatives and the money we put toward registering new products, we also see an opportunity to build our complex PCI franchise throughout Europe, given that the Vascular Intervention business is strongly positioned in that market. Strong R&D, clinical know-how and worldwide manufacturing capacity are essential components of the Vascular Intervention business that we anticipate acquiring. Every one of these should further bolster Teleflex's innovation pipeline and let the company introduce new products and enhance patient care; we will keep investing in creating highly competitive interventional offerings, among them differentiated new technologies such as the resorbable metallic scaffold. Along with our broad global footprint, we intend to bring innovative technologies to interventionalists, furthering clinical benefits and safety for physicians as well as patients. Buying the Vascular Intervention business will additionally give Teleflex the chance to put money into and grow the clinical trial program for Biotronik's Freesolve, a sirolimus-eluding resorbable metallic scaffold technology, including a possible push into the U.S. market. Freesolve could help move interventional coronary and endovascular procedures toward leaving behind less permanent hardware. We think Freesolve demonstrates early promise in tackling the shortcomings of earlier polymeric resorbable scaffolds, delivering faster absorption, thinner struts and metallic mechanical performance. Freesolve has already shown compelling clinical data in the BIOMAG-I study, a first-in-human trial conducted at 14 European centers. Freesolve obtained CE mark for treating de novo coronary stenosis in February 2024, based largely on the safety and efficacy of its predecessor, Magmaris. Enrollment is underway right now for the BIOMAG-II pivotal trial in Europe, and we expect to see the first data from it during 2027. Turning to how the business we intend to purchase looks financially: our expectation is that the deal will close before the third quarter of 2025 is over, assuming the usual conditions are satisfied, including getting specific regulatory clearances. Should that schedule be met, we intend to revise our guidance during the third quarter 2025 earnings conference calls. Since 2022, the Biotronik products we plan to buy have posted a constant currency revenue CADR of 5.4%. Based on when closing is expected to occur, those Biotronik products ought to bring in roughly EUR 91 million of revenue during the fourth quarter of 2025. Beginning in 2026, we anticipate that buying Biotronik will generate constant currency revenue increases of at least 6%. For the products we plan to pick up, adjusted gross margin is in line with the Teleflex company-wide average. Because we'll keep investing heavily to push forward the pipeline and Freesolve, this deal ought to dilute Teleflex adjusted operating margins. As revenue from the Biotronik purchase expands, we look for operating margin leverage to build over time. Turning to the bottom line, during the initial year of ownership counted from the closing date, we expect roughly $0.10 of accretion to our adjusted earnings per share, with growing accretion after that. Bringing the Vascular Intervention business into the fold should generate double-digit ROIC at an early point in year 4 once the deal has closed. Our initial approach to funding this acquisition would rely on a new term loan, revolving borrowings drawn under the senior credit facility we already have in place, and cash we hold on hand. On top of that, we have signed foreign exchange derivative contracts as an economic hedge against the currency risk tied to the cash consideration required to get the acquisition done. While working through the process of acquiring the Biotronik Vascular Intervention business, we also carried out a thorough evaluation of our business portfolio. Following that review, we're sharing today that Teleflex's Board of Directors has given management the go-ahead to move forward with a plan that would divide the business into two separate, independently listed public companies — RemainCo and NewCo. This split fits the strategy we've already laid out for the company: refining our product lineup while pushing adjusted margins and adjusted earnings per share higher. Through this separation, we aim to unlock more value for everyone holding Teleflex stock. By forming two distinct publicly traded entities, each one would be set up to speed up its own growth thanks to a leaner operating structure and sharper management attention. Splitting up will permit better allocation of resources toward the distinct strengths and opportunities belonging to each business, giving investors an investment opportunity that is more targeted.

Liam Kelly

executive
#6

This setup will additionally allow for separate approaches to deploying capital that fit more closely with what each standalone business wants to achieve and how it thinks about growth. Let me walk you through the deal now. Teleflex is going to spin off a brand-new, independently listed, publicly traded entity holding the Urology, Acute Care, and OEM operations. For U.S. tax purposes, the plan is for this deal to take the form of a tax-free distribution of freshly issued NewCo stock to shareholders. As I said earlier, splitting the businesses will let each one speed up its growth thanks to a simpler operating model and more dedicated management attention. Both RemainCo and NewCo should end up capitalized in a suitable way, each with its own clear and rigorous set of capital deployment priorities. At the moment of separation, RemainCo was anticipated to post constant currency revenue growth of 6% or more, lift Teleflex's adjusted gross margin, and initially come in neutral on Teleflex's adjusted operating margin, partly because of larger planned spending on R&D. Once the first full year after separation is behind us, we anticipate delivering adjusted earnings per share growth in the double digits. I'll stay on to head RemainCo as Chairman, President and CEO. We'll announce who will lead NewCo over the next few months, and we anticipate closing the deal around mid-2026, assuming market, regulatory and certain other conditions are satisfied. Let me go deeper now into why having 2 leading, focused, independent companies pays off. On the RemainCo side, the separation produces a leaner portfolio centered on business units that complement one another strongly: Vascular Access, Interventional and Surgical. Notably, picking up substantially all of the Biotronik Vascular Intervention business plays a key part in the plan to build an operation with a meaningful worldwide footprint in the cath lab, backed by stepped-up investment to advance the new technology pipeline. With this tighter portfolio, RemainCo will be better placed to take advantage of end markets that grow quickly, involve high acuity, and center on hospitals; we think this more agile operating model and a simplified manufacturing footprint will open up chances for margin expansion down the road and free up capacity for bigger, sharply targeted R&D spending. Lastly, RemainCo will gain the ability to line up its capital deployment approach completely with its growth plan, strengthening its hand to chase business development deals so it can compete more effectively in end markets defined by high innovation. Turning to NewCo: this operating setup lets management concentrate without distraction on realizing NewCo's potential through a simpler operating model. NewCo will compete in appealing end markets across Urology, Acute Care and OEM, and it will be set up to build on the market positions it has already established in those respective areas. Through a capital deployment and investment approach tailored to its needs, the company can spot, fund and seize opportunities unique to the urology, acute care and OEM end markets in order to fuel innovation and growth. The urology markets still hold substantial room to grow, while OEM will be free to broaden its customer base further and strengthen capabilities that weren't accessible across all parts of Teleflex. This separation will set up both RemainCo and NewCo for sharper corporate definition and stronger strategic focus. RemainCo, which would have brought in roughly $2.1 billion of revenue in 2024 on a pro forma basis after buying the Vascular Intervention products from Biotronik, is going to be in a stronger spot to take advantage of appealing high-growth end markets. Those markets serve emerging procedures done mainly in hospital settings, spanning the intensive care unit, emergency department, cath lab and operating room. The RemainCo product portfolio is going to be extremely complementary, with considerable breadth throughout the hospital, leading market positions and growth opportunities spread across 3 distinct business units. Vascular, Interventional and surgical. Vascular access is going to cover products made up mostly of our catheters carrying the Arrow brand, systems for catheter navigation and tip positioning, plus our intraosseous access systems. Once separation happens, vascular access is also going to bring in our emergency medicine portfolio, which includes hemostatic products sold under the QuikClot trade name. Interventional is going to be made up mainly of an assortment of coronary catheters and structural heart support devices that interventional cardiologists, interventional radiologists and vascular surgeons use. The Interventional product categories are also going to contain the Biotronik Vascular Intervention business — the agreed upon acquisition of which we announced today and expect to close by the end of the third quarter of 2025 — significantly expanding our portfolio in both coronary and peripheral cath lab procedures. Surgical is going to cover single-use and reusable devices built for use in an assortment of surgical procedures. Mostly this means metal and polymer ligation clips, a facial closure surgical system used in laparoscopic surgical procedures, percutaneous surgical systems, a power bariatric stapler and other surgical instruments used in ear, nose and throat and cardiovascular and thoracic procedures. NewCo, with roughly $1.4 billion in 2024 revenue, is going to have a stronger ability to spot, put money into and take advantage of opportunities that are unique to the company's business units and end markets. NewCo is going to be a diversified acute and extended care company focused on Urology, acute care and OEM markets. Urology is going to include the company's interventional urology and bladder management portfolio. Key products and brands are going to include the UroLift System for the treatment of BPH. Barrigel rectal spacer for use in radiation therapy for prostate cancer and the Rusch brand of catheters and bladder management products. Acute care is going to include the majority of Teleflex's anesthesia product category as well as our respiratory product category, portfolio of intra-aortic balloon pumps and select other products. OEM is going to stay focused on the design, manufacture and supply of devices and instruments for other medical device manufacturers. The OEM business specializes in custom extrusions microcatheters and specialized sutures. RemainCo and NewCo are going to benefit from more nimble operating models and a simplified manufacturing footprint. The operating model is going to be simplified from 7 product categories today to 3 product categories in each company post separation. From a manufacturing footprint perspective, the separation results in significantly streamlined operations for both companies. RemainCo is going to have a simplified and nimble operating model with a streamlined manufacturing footprint, transitioning from 19 anticipated manufacturing facilities at Teleflex inclusive of the Biotronik Vascular Interventions business as of year-end 2025 to 7 facilities at RemainCo post separation with the remaining trials to transfer to NewCo. What matters here is that the way NewCo's operations and production sites are laid out should make splitting off simpler. Now, some further details about RemainCo. RemainCo's attention will be on product categories that fit together well, serving end markets centered on hospitals. Vascular Access, Interventional and Surgical are among the markets it serves, together worth roughly $32 billion, and they are expanding at a rate above the mid-single-digit level. Once separated, RemainCo should deliver constant currency revenue growth of 6% or more, add right away to Teleflex adjusted gross margin, which has a mid-60% profile, and at first is anticipated to be neutral for Teleflex adjusted operating margin, in part because R&D investment is expected to be higher. A leaner operating model would open the door to margin gains down the road and free up room for more targeted R&D spending. Also, the deal should produce double-digit adjusted earnings per share growth across the first full year after separation. Let's move to how RemainCo plans to allocate capital. With a stronger financial profile after the separation, RemainCo gains more flexibility to bring its capital allocation approach and growth strategy into closer alignment. The company will stay disciplined.

Liam Kelly

executive
#7

Our capital plan starts with directing funds toward our own high-return growth initiatives, then toward acquisitions that add growth and sharpen how well we compete in end markets defined by rapid innovation; we also intend to pay down debt where it makes sense in order to keep our leverage profile in good shape, while still giving money back to shareholders through a quarterly dividend and buying back stock when opportunities arise. Under this approach to deploying capital, Teleflex aims for a net leverage ratio under 3x through 2026. Now on to NewCo. NewCo holds a robust portfolio across established end markets projected to expand in the low to mid-single-digit range and worth more than $40 billion altogether. It will enjoy a solid call point across hospital, ASC and office sites of service. On top of that, via NewCo's OEM business, the company should carry strong ties with fellow medical device makers that rely on its considerable design and manufacturing expertise. Once the separation is complete, NewCo is projected to deliver low single-digit constant currency revenue growth alongside a gross margin profile in the mid-50% range. Looking out over the medium term, NewCo could speed growth up to low to mid-single digits as the UroLift business bounces back, Barrigel keeps up strong momentum alongside chances to widen the addressable market via new FDA-cleared indications, and the OEM business works to get back to its historical growth, helped by more freedom to grow the customer base further and by stronger capabilities. A simpler operating model will work in the company's favor, letting it direct investment toward growth drivers and allocate capital for its investors. As noted, NewCo could lift growth from low single digits at the moment of separation up to mid-single digits, with urology and OEM serving as the main drivers. Within urology, efforts will center on steadying UroLift past 2025. This year is the last one in the phased reimbursement cut in the United States tied to the site of service. The team is concentrating on boosting usage via strategies specific to each site of service, plus ongoing work on UroLift 3, which we think will produce better economics and sustain the base of solid scientific evidence backing the technology's use. Palette revenue came in slightly above the top end of the 2024 guidance range of $73 million to $75 million, which means growth beyond 30%. Going forward, we still anticipate healthy double-digit growth. On the OEM side, we view the factors weighing on revenue growth in 2025 as temporary, coming after a lengthy stretch of revenue gains featuring a 9.5% CAGR from 2014 to 2023. The effect of customer vertical integration will anniversary in the middle of 2025, and customer inventory management should mostly play out over the course of the year. After the separation, OEM will be free to grow the customer base further and strengthen capabilities; that wraps up my prepared remarks. At this point I'd like to hand the call back to the operator for Q&A.

Patrick Wood

analyst
#8

I think maybe I'd like to begin with the reasoning behind the timing — how we arrived at this point. I'm just wondering what triggered the review? How did you decide that right now is the correct strategic moment for all of this, since there are still plenty of changes, obviously. And I'd appreciate a bit of the timeline there. Then I have a quick follow-up.

Liam Kelly

executive
#9

Yes, Patrick. As we've talked about on numerous occasions, Teleflex performs portfolio reviews on an ongoing basis as a disciplined management team — among the central pillars of our value creation framework is optimizing our product portfolio. So we were continually assessing options to get the most out of every one of the businesses and get the most value for shareholders. If you look back at Teleflex's history, we've been through a major evolution regarding company focus. Starting as a rather diversified industrial company, if you go back to the 1900s, we then concentrated on turning into a true pure-play medical device company and completed many acquisitions and divestitures during the 2000s; we think this is the right moment, especially given the addition of the Biotronik Vascular Intervention business that we are announcing today as well, it's obvious to us that we would genuinely have 2 businesses in — with differing growth strategies, differing goals, capital allocations priorities, and both of them would gain from being independent companies. If you look at RemainCo and NewCo, their growth and profitability profiles are fundamentally different, with the value not fully realized within either of them while they're combined inside Teleflex. Once we reached that understanding, we began to examine this from a logistical standpoint and it was in fact a fairly clean separation. Our manufacturing footprint in operations today are already mostly aligned to this separation. The Urology business and OEM business are readily separable entities within Teleflex today. So the strategic rationale was present. And then when we actually examined how feasible it would be logistically and operationally, those pieces all really fell into place. So after examining multiple ways to drive value with these businesses, we felt that a separation at this time is the most significant way we can drive value for our shareholders, our businesses and our team members.

Patrick Wood

analyst
#10

That's really useful, and I'll just jump in quickly with one more. Clearly we've talked about Vascular a handful of times, you and I, and that particular area. What's your thinking around the sales force and access on a relative basis, since Biotronik is clearly extremely strong across EMEA? I'm just trying to work through it — you've clearly got a larger bag for the reps. Could the reps be consolidated in any way? Or is it a case where, given that the geographic split differs somewhat between the two of you, you retain all of them and simply make the bag bigger?

Liam Kelly

executive
#11

I think you've nailed it — on a synergistic basis, when it comes to the Biotronik acquisition, Teleflex's Interventional business is far stronger across the Americas. Biotronik's business is far stronger across EMEA. So now, by bringing the Vascular Interventions business together with the Teleflex business, we can capitalize on both of those regions. In addition, as I mentioned in my prepared remarks, within Teleflex we already have products approved for peripheral access, yet we've never had a channel to sell those products through in the United States and in Europe. That opens up the chance for us to do exactly that. And regarding where the Biotronik Vascular Interventions business gets sold in the United States — obviously, it's a smaller company. So it's hard for their people to get access to the cath lab, while Teleflex has no trouble getting that cath lab access. Of course, the two businesses complement each other very well. One small example for you. Their <<inaudible>> drug-eluting stent is genuinely well suited to those tortuous coronary arteries, thanks to its flexibility and my ability to place it. That's precisely where a broad portion of our portfolio gets used each and every day to gain access for placing these products.

Matthew O'Brien

analyst
#12

Tom, I wish you all the best going forward. Liam, when I look at the assets you're picking up here, Freesolve catches my attention, even though this category of bio-resorbable offerings has historically been tough. Could you walk us through what you're gaining with this asset, and the conviction that you can hit the growth you're describing from it? Maybe it's more of an OUS expansion story down the road; but beyond that, what about the capacity to build on things once you've got this in-house, when RemainCo exists later on, and how might that play out? Because I suspect certain folks will harbor some doubt, simply because you're folding in technologies that are somewhat older by nature, for want of a better phrase.

Liam Kelly

executive
#13

Looking at the portfolio, several important products sit inside it. There's the PK Papyrus, a covered stent, and it's genuinely among the few covered stents out there, with a distinctive set of applications. Then there's the Pantera, the Pantera Pro drug-coated balloon, which posted a very strong CAGR across the past few years. And you also have the peripheral Passeo drug-coated balloon, with very strong rates. On what you said about Freesolve: I'd highlight that the earlier products used polymer, while this one is metallic; in my view that provides us with attractive optionality for revenue growth later on as the clinical trial proceeds. When we examine the CAGR for the portfolio being acquired — and to be precise, we are not buying the entire portfolio of the Vascular Interventions business — looking at how that portfolio's CAGR has performed over the past few years, it comes to 5.4%. And on top of that, there were volume-based procurement effects in late 2024 in China. Normalizing for those, this portfolio's CAGR would exceed 6%; so it already has a strong growth profile, it contains some innovative products, and it fits Teleflex very well, both by geography and through synergies with our existing portfolio; plus it hands us a considerably larger footprint in the cath lab across both Europe and the United States, and it will open up the chance for possible go-direct moves much like what occurred when we bought Vascular Solutions back in 2017.

Matthew O'Brien

analyst
#14

Understood. Then, one more question regarding the acquisition. Could you — would you mind expanding a bit on what the real sales figures are? I'm not sure whether you or Tom would prefer to address the sales and the margin profile? And then, why do you both believe you're able to actually expand this business at a superior rate compared to what Biotronik was achieving?

Liam Kelly

executive
#15

Sure. On the sales figure, I provided the growth rate for the acquisitions that we brought in. As we laid out, our plan is to close late Q3. And like I mentioned during my prepared remarks, that amounts to roughly EUR 91 million in the fourth quarter. Seasonality isn't very pronounced in this business, though there's a bit during the summer. But if you — so, as a result, you simply take that EUR 91 million, which comes to about $94 million, and that would work out to approximately $375 million on a full year basis; and what we expect, given the synergies from bringing this product family into Teleflex, is that it will grow 6% or better starting in 2026 and beyond. And then, as I mentioned, you have the optionality of Freesolve going forward.

Jayson Bedford

analyst
#16

Tom, congratulations on your retirement. I might ask 2 questions, and I'll put both out there right away. Liam, I would really like to hear your reasoning for choosing to remain with RemainCo rather than going to NewCo. Then second, during the comprehensive business review, did you seriously consider selling off parts of the business instead of doing a spin?

Liam Kelly

executive
#17

Right. My plan is to remain at RemainCo — the Board has requested that I stay and oversee the splitting of the 2 companies — and I intend to carry that through and push this business toward growth above 6% with a gross margin and operating margin in the mid-60s, matching what the Teleflex company achieves. As I mentioned before regarding a sale or a spin, we intend to keep funding R&D inside this business. When we assessed our portfolio and considered Biotronik's business joining, we concluded that the most efficient path to unlock shareholder value is to separate these 2 businesses. We are highly focused on generating that shareholder value, and our base case for the separation, as announced today, is meant to be a tax-free distribution through a spin-off. But Jayson, you know that lately, a number of deals like this that were announced began as a spin and ultimately wound up being sold, and honestly, should that chance arise and deliver more value for shareholders, we will be willing to go after it.

Shagun Singh Chadha

analyst
#18

I suppose my hope was that you might say something about the 2025 outlook of 1% to 2% constant currency, since it caught me somewhat off guard? What caused this kind of dramatic adjustment to your business? Could you perhaps discuss how Q4 trended and what you see for '25? And regarding RemainCo specifically, what actually makes you confident that you can achieve that 6% ex FX growth reliably once the separation happens in mid-2026 and afterward?

Liam Kelly

executive
#19

Fine, Shagun. I'll address the latter portion initially. What makes us confident RemainCo could deliver growth of 6%-plus? Well, should you examine the 2025 guidance and our 2025 plan, excluding the effect of volume-based procurement in China, that business is expanding in the high 5s. Clearly, also inside our plan, RemainCo faces challenges, and I'll address that shortly as I walk through the guidance. So the 1% to 2% guidance genuinely mirrors the trading environment we foresee across the 12 months. Our guidance anticipates the Americas and APAC will each grow low single digits, whereas EMEA will expand in the mid-single digits. UroLift has carried on. We expect it to face challenges throughout the year. And we likewise expect Palette to expand consistent with our earlier expectations. Yet we've told the investment community repeatedly that in 2025, we aren't anticipating any improvement in conditions for UroLift. This marks the final year of reimbursement. So that might be something that shifts later on. For OEM, tighter inventory management from our customers is now what we expect in 2025. We've contacted every one of our customers to obtain order levels for 2025, and it now seems that the inventory management we saw in the second half of 2024 will speed up as we move into 2025. We already had, as we relayed, an effect in the first half of 2025 in OEM stemming from vertical integration, but now we observe that being compounded by stronger inventory management during that stretch. The third headwind sits in APAC, where we anticipate being affected by volume-based procurement in our Surgical business in 2025. This, once more, similar to the OEM effect, we think, would be temporary and mostly worked through during 2025. And that is why it's lowering the — our expectation for APAC growth down to the lower single digits. And the effect is located within China. If you add up those 3 categories of headwinds, Shagun, that comes to roughly $100 million, with UroLift being the biggest, OEM coming next and volume-based procurement ranking third.

Larry Biegelsen

analyst
#20

Congrats, Tom. I've got a few questions, I suppose one about Biotronik and another about the separation. So Liam, perhaps focusing specifically on the Biotronik products, could you describe the strategy for Pantera Lux in the U.S. and Freesolve in the U.S., and when are you able to begin the pivotal trial? Then I have a follow-up regarding the separation.

Liam Kelly

executive
#21

All right. As for what you asked about that product, its clinical data is excellent. What we've observed is that the way that clinical data gets presented might be better. And I believe Teleflex contributing our clinical know-how to that presentation — it is especially well suited to stent placements that are more tortuous, thanks to the flexibility and thin wires of that particular stent. Pantera would need some work on coating technology to bring it broadly into the U.S.; at this point, we've announced that we will sign the — we signed the agreement today; the product won't be closed until the end of Q3. As for Freesolve, our expectation is that we'll keep going with the clinical study in Europe, get that finished, and we'll update the investment community and our plans for Freesolve for the United States as we move through 2026, but for us it's a nice revenue optionality in the future, Larry.

Larry Biegelsen

analyst
#22

All right, that's useful. Now for my second question: given the separation, when it comes to each unit's margins as they stand now, I couldn't find SpinCo's operating margin, and you described RemainCo as roughly neutral while investments rise. Could you break out the components for us today, so we can obviously build distinct models? Also, any detail on stranded and standup costs for both. Is looking at recent precedents the right approach?

Liam Kelly

executive
#23

Yeah. On stranded and stand-up costs, Larry, I'd say you're quite close. Precedents are what you should examine; our view is this will be — though no two spins are alike. We expect it to resemble a lot of those; we've aimed to provide the investment community with maximum color, with RemainCo expanding at plus 6% at mid-60s gross margin, putting money into R&D with operating margins comparable to Teleflex. Likewise for NewCo, our expectation is growth in low single digits, with room to get better as the urology business and the OEM business strengthen over time. Its gross margin will be mid-50s. Clearly, much of the remaining detail will come out in the Form 10, but my view is you ought to treat it as comparable, comparable carve-outs, Larry. That's a solid benchmark to apply.

Anthony Petrone

analyst
#24

Tom, congrats. Best of luck with the transition. Maybe staying on the spin's structure, Liam, is the parent going to keep any ownership stake in the spin? How would that play out? Any thoughts on the capital structures for the 2 businesses — the consolidated business is holding around $1.65 billion in debt. So any early views on how the debt for each of the standalone businesses will shake out? And then I'll have one quick follow-up on Biotronik.

Liam Kelly

executive
#25

Yes. Just on the capital structure, Anthony, all of that is going to be determined as we go through, and also the determination as to what holding RemainCo would have within NewCo, and obviously, all of that would be disclosed in the Form 10. It's our intent to set up 2 very successful companies. And all of this is going to be defined over the next several quarters. We do want a RemainCo and a NewCo with a strong viable future, both making independent decisions for their companies to extract shareholder value from both RemainCo and NewCo.

Anthony Petrone

analyst
#26

Then regarding Biotronik, could you touch a bit on the potential for top line synergies and also cost synergy? On the top line, definitely, channel overlaps exist with Vascular Access, perhaps somewhat, Interventional, Surgical might be distinct, and then geographically, it appears synergies could be present there. And then just regarding cost synergies. So just a bit on the sales synergy of ParentCo with Biotronik and also cost synergy?

Liam Kelly

executive
#27

Like I mentioned slightly earlier, we possess a variety of our existing products that carry an indication for peripheral, yet we have lacked a channel to sell those products together. I believe there is a substantial opportunity for us in merging the sales forces in both the U.S; and in Europe to have a bigger bag and be more pertinent within that cath lab call point. We've stated repeatedly the cat lab is a call point that we truly wish to keep exploring and we want to keep investing behind the new product innovation; that's the lifeblood of these products. So we'll now have an entire suite of products available with a full bag sales organization in the cath lab for both coronary and peripheral indications, and we will be capable of selling our products that have a peripheral indication through that sales channel, gaining synergies in that respect. So your analysis is — and perception is completely correct. There will be opportunities as we merge the bags of both companies and the sales forces of both companies to help drive that growth of 6% or better as we move forward.

Richard Newitter

analyst
#28

Tom, I also want to congratulate you on retiring. I've got a few things to start with here. With all the news coming out, forgive me if these seem like stale subjects, but is there anything new on the intra-aortic balloon pump forecast timeline and your thoughts about the competitive landscape in that sector, plus the chance for you to pick up share there? I'd also like to ask how, if at all, tariff exposure is factored into the '25 outlook. And could you remind us how that flows through your business and what your exposure amounts to there? Then finally, do you have any sense of who will lead NewCo? Will you look internally or externally, or is it too early?

Liam Kelly

executive
#29

All right. I'll handle 2, and I'll have John address the tariffs; as for the management team at NewCo, we're starting a search right away for that management team. Obviously, some internal people will move over to run that business. But our intent is to launch an external search for a new NewCo CEO and CFO. On the intra-aortic balloon pumps, Rich, nothing has changed in our outlook and expectation; in Q4 for intra-aortic balloon pumps, we came in slightly ahead of what we expected. As we moved through Q4 and into early Q1, the quotation rates have stayed robust, and we see the opportunity through Q1 and Q2 as being what we had communicated previously. And I'll have John give you some additional color on the tariffs.

John Deren

executive
#30

Absolutely. The tariffs that are already in effect are reflected in what we've planned for. As for the tariffs the Trump administration has suggested on multiple occasions but hasn't actually implemented, our greatest vulnerability continues to be the possibility of a tariff on Mexico, since our operations there are substantial, and that scenario would hit the company hardest.

Craig Bijou

analyst
#31

Tom, congratulations on your retirement. Just a few quick things from me. Perhaps a follow-up to what Rich asked regarding tariffs. I mean, could you possibly quantify how much exposure there would be if the tariffs on Mexico took effect? And then regarding the OEM business and what you said, Liam, I suppose I just wanted to get a clearer picture: do you view this as a wider inventory reduction effort? Or are there particular items in your portfolio that your customers might be singling out to draw down that inventory?

Liam Kelly

executive
#32

Right, Craig. So where inventory is concerned, it's fairly widespread across the board. Over the last 2 years, we observed customers starting up, especially with certain extrusions — complex extrusions; and in that segment we're likely witnessing a somewhat disproportionate normalization. As for the tariffs, there's considerable uncertainty surrounding them, and things aren't very clear. Might medical devices get exceptions? Is the impact limited to value add? In what way is the Maquiladora arrangement being handled? It's tough to operate your company while predicting all this according to whatever tweet comes out that day. Clearly, as we saw last night, there's now an intent regarding Europe. And once more, there's an utter absence of clarity about how that. So for a fuller response, we genuinely require additional details. Naturally, we are taking steps. We've shifted inventory to the north side of the border, and as you're likely aware, Craig, should tariffs actually land, much of that would be capitalized into your inventory and afterward would work its way out somewhat later in the cycle. So it's hard to provide you with particulars about the assorted tariffs. Yet, as John mentioned previously, every tariff currently in effect is factored into our — the guidance we gave.

Mike Polark

analyst
#33

Why are the balloon pumps heading to NewCo instead of staying with RemainCo?

Liam Kelly

executive
#34

Honestly, Mike, that subject definitely came up in our talks, yet the truth is those products genuinely belong within that acute care space. There's a dedicated sales team just for them, and they'll bring added value to NewCo. Given how the margins look, they made more sense under NewCo rather than RemainCo. And clearly, they come with their own distinct manufacturing setup. So yes, it got debated. In the end, after the team spent the past several months working through it, this is where we landed.

Mike Polark

analyst
#35

My next one is along the same lines, except it concerns anesthesia. In my mind, that area complements vascular access quite well — same call point, critical care settings, ICU emergency med. What am I not seeing? Is it a sales issue — does it need its own sales force? Does it carry a materially lower margin profile, or price risk — why split those 2 apart?

Liam Kelly

executive
#36

Sure. So broadly speaking, the anesthesia business covers regional anesthesia and ICU/operating room, general anesthesia. Honestly, Mike, there aren't that many synergies with the vascular business. The single part of that business that does have synergy with the vascular business is the emergency medicine piece of it. And clearly, that is staying with RemainCo, and clearly, the margin profile and growth profile of the anesthesia without the emergency medicine side of it would probably fit better in NewCo than in RemainCo.

Mike Matson

analyst
#37

I’d like to ask about the Biotronik transaction. I believe you mentioned that this business’s gross margin is comparable to the gross margin we currently have at the corporate level. Is that accurate? And that seems somewhat lower than my expectation. Could that be due to a greater sales mix exposure to OUS and Europe? Also, if you begin selling more of those items in the U.S., where prices are higher, is there a chance to gain some gross margin improvement there?

Liam Kelly

executive
#38

Yes, so it matches Teleflex. You heard that right, and that’s true. Right now there’s a sizable amount of investment going into this business regarding the pipeline, especially with the optionality I mentioned for Freesolve, and I think your point is accurate. As we can speed up growth within the United States, and as we speed up parts of the new product pipeline, there’s a possibility to enhance that gross margin over time, and clearly there’s certainly a chance to enhance operating margin over time.

Mike Matson

analyst
#39

All right, understood. Moving to Freesolve — sorry if this was covered already, but would it be necessary to conduct a U.S. pivotal trial should you choose to pursue commercialization there, or are the existing trials sufficient?

Liam Kelly

executive
#40

The trial currently underway is designed for Europe. So yes, you're correct. A U.S. trial would be required on our part. And like I mentioned before, during 2026 we'll keep the investment community informed regarding our optionality on that front; by then we'll have enrolled significantly more patients in the European trial, and our visibility into what the U.S. pathway looks like will be considerably clearer at that point.

Larry Keusch

executive
#41

Appreciate that, Sarah, and thanks as well to all of you who took the time to be with us on today's call. That brings the Teleflex Incorporated Fourth Quarter 2024 Earnings Conference Call to a close.

Operator

operator
#42

Thank you. You may now disconnect.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Teleflex Incorporated transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Teleflex Incorporated earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Teleflex Incorporated or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.